| Dr Joanna Leyenaar, MD | |
|
1 Medical Center Dr, Dartmouth Hitchcock - Pediatric Hospital Medicine, Lebanon, NH 03756-1000 | |
| (603) 653-6063 | |
| Not Available |
| Full Name | Dr Joanna Leyenaar |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083947659 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 17884 (New Hampshire) | Primary |
| 208000000X | Pediatrics | 242288 (Massachusetts) | Secondary |
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
Computer technology that provides parents with customized safety information can be an effective way to help their children avoid injury, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.
In what may be a hopelessly quixotic effort, supporters of the federal Children's Health Insurance Program are trying to persuade Congress to renew its funding almost a year in advance -; and in a lame-duck session. Nevertheless, lawmakers ought to heed that call. The program plugs a troubling gap between Medicaid and the Affordable Care Act's subsidized plans, and states need to know whether they can count on federal funding or whether they will have to spend far more dollars of their own (10/21).
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Researchers at Oregon Health & Science University's Neurological Sciences Institute (NSI) have located a possible target for future therapies aimed at delaying or stopping Alzheimer's disease.
› Verified 3 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
Computer technology that provides parents with customized safety information can be an effective way to help their children avoid injury, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.
In what may be a hopelessly quixotic effort, supporters of the federal Children's Health Insurance Program are trying to persuade Congress to renew its funding almost a year in advance -; and in a lame-duck session. Nevertheless, lawmakers ought to heed that call. The program plugs a troubling gap between Medicaid and the Affordable Care Act's subsidized plans, and states need to know whether they can count on federal funding or whether they will have to spend far more dollars of their own (10/21).
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Researchers at Oregon Health & Science University's Neurological Sciences Institute (NSI) have located a possible target for future therapies aimed at delaying or stopping Alzheimer's disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joanna Leyenaar, MD 1 Medical Center Dr, Dartmouth Hitchcock - Pediatric Hospital Medicine, Lebanon, NH 03756-1000 Ph: (603) 653-6063 | Dr Joanna Leyenaar, MD 1 Medical Center Dr, Dartmouth Hitchcock - Pediatric Hospital Medicine, Lebanon, NH 03756-1000 Ph: (603) 653-6063 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
Computer technology that provides parents with customized safety information can be an effective way to help their children avoid injury, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.
In what may be a hopelessly quixotic effort, supporters of the federal Children's Health Insurance Program are trying to persuade Congress to renew its funding almost a year in advance -; and in a lame-duck session. Nevertheless, lawmakers ought to heed that call. The program plugs a troubling gap between Medicaid and the Affordable Care Act's subsidized plans, and states need to know whether they can count on federal funding or whether they will have to spend far more dollars of their own (10/21).
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Researchers at Oregon Health & Science University's Neurological Sciences Institute (NSI) have located a possible target for future therapies aimed at delaying or stopping Alzheimer's disease.
› Verified 3 days ago
Sheila L Feyrer, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5 Alice Peck Day Dr, Lebanon, NH 03766 Phone: 603-448-3122 Fax: 603-448-7491 | |
Scott Shipman, MD, MPH Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-9337 | |
Dr. Julie Lucy Sanville, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: One Medical Center Drive, Gastroenterology, Lebanon, NH 03756 Phone: 603-653-9666 Fax: 603-653-9166 | |
Dr. Torunn Thorsen Rhodes, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-6063 | |
Kimberly Molina, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Dr. Tricia Lynn Groff, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Dhmc Department Of Pediatrics, Lebanon, NH 03756 Phone: 603-653-9663 | |
Paul Eric Palumbo, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Infectious Disease - Dartmouth-hitchcock Med Ctr, Lebanon, NH 03756 Phone: 603-650-8840 Fax: 603-650-6199 |